Inflammatory bowel disease (IBD) is a chronic inflammatory condition of unknown etiology that can develop in any portion of the digestive tract but which has a high incidence especially in the terminal ileum and/or in the colon. The diagnosis and management of IBD, including Crohn's disease (CD) and ulcerative colitis (UC), is still challenging, and the presence of intestinal inflammation is, to date, a primary criterion for its diagnosis and differentiation from other diseases. Moreover, there is no decisive gold standard diagnostic test based on patient history and physical examination, supplemented with objective laboratory, radiological, endoscopic and histological findings.
Introduction
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of unknown etiology that can develop in any portion of the digestive tract but which has a high incidence especially in the terminal ileum and/or the colon [1] . IBD can be sub-grouped into two common forms, precisely Crohn's disease (CD) and ulcerative colitis (UC). Previous studies reported that the disease pathogenesis involves genetic factors, an abnormal immune response to microbial infections and gut-microbiota imbalance [2] [3] [4] [5] .
Current treatment focuses on reducing and controlling inflammation. There is no cure, and the majority of IBD patients remain under medical care and management for life [6] .
Diagnosis and management of IBD is still a challenge because the presence of intestinal inflammation is a primary criterion for diagnosis and differentiation from other diseases, but no decisive diagnostic tests are available. The diagnosis is based on patient history and physical examination, along with laboratory, radiological, endoscopic and histological findings [7] .
Discovering new biomarkers is a challenging process, and researchers have not been entirely successful at uncovering biomarkers that can reliably differentiate IBD patients from healthy controls, CD from UC, or predict disease outcome or response to treatment [8] .
Recently, Piras et al. investigated the serum proteomic profile of early and advanced CD in order to identify differentially expressed proteins in acute CD and during the course of the disease. Inflammatory proteins and complement C3 chain (C3c) were over-represented during early CD, while clusterin, retinol-binding protein, a1-microglubin and transthyretin were under-represented [9] . Moreover, C-reactive protein (CRP) correlates with disease activity and prognosis of IBD, but its specificity is insufficient [10, 11] . Although fecal markers, such as calprotectin or lactoferrin, are currently being tested or used as diagnostic tools for the evaluation of IBD, results have been largely unsatisfactory, especially in terms of clinical outcome and response to therapy. For instance, calprotectin, as biomarker of IBD, presents several limitations, such as poor specificity, no validated cut off value to define active disease/clinical remission, and dependence on physiological factors [12] .
Lipids play a pivotal role in IBD pathogenesis since they are a static metabolic energy reserve that is employed in cellular signal transduction pathways. Lipids are involved in chronic intestinal inflammation, and several studies have focused on dietary lipids, the role of lipids in mucosal immunity, lipids in inflammatory signal transduction, alterations in lipids associated with the emergence of chronic inflammation, and lipid-based therapies [13] [14] [15] [16] .
This study adopted a multi-omics approach to analyze plasma proteins and lipids in UC and CD patients at a very early stage of diagnosis or presenting with mild symptoms. Interest in the quantitation of large proteomes across multiple samples has rapidly increased in recent years, especially stimulated by the development of new instruments and tools. Moreover, low-abundance human plasma proteins are considered the most promising biomarkers for disease diagnosis and therapeutic monitoring.
We used an immunodepletion method to reduce the levels of the 14 high-abundance proteins, followed by shotgun proteomics with liquid chromatography mass spectrometry (LC-MS/MS). We also investigated the role of serum fatty acids, which are very important because their expression can be modulated during inflammatory processes. Several fatty acids were simultaneously quantified using gas chromatography mass spectrometry (GC-MS). The bioinformatic and multivariate analysis of the proteomic and lipidomic fingerprint of patients' serum samples allowed to identify several potential biomarkers and pathways involved in the pathology.
Materials and Methods

Selection of Subjects
Fifteen patients with Crohn's disease (CD: 7 men and 8 women, mean age 47 years, range 30-65 years) and 13 patients with ulcerative colitis (UC: 8 men and 5 women, mean age 56 years, range 39-75 years) from the Gastroenterology and Hepatology Department, Città della Salute e della Scienza, Molinette Hospital (Turin, Italy) were enrolled in this study. All diagnoses had been previously confirmed by clinical, endoscopic, and histological criteria.
At the time of enrollment, serum samples were collected and stored at -80°C until use, and clinical and serological features were recorded. All patients selected for this study had a low or moderate disease activity (Harvey-Bradshaw Index (HBI) for patients with CD; Mayo score for patients with UC). The demographic, clinical, and laboratory data obtained at the time of blood sampling are reported in Table 1 .
Written informed consent was obtained from all participants as established by the Declaration of Helsinki, and approval of the study protocol was obtained from the local ethics committees.
Chemicals
All chemicals and materials, if not specifically stated otherwise, were purchased from Sigma-Aldrich, St Louis, MO, USA.
Sample preparation procedure for serum proteome and fatty acid profiles
12 μL of sera were depleted of high-abundance proteins using the Seppro IgY14 spin column kit (Sigma-Aldrich Inc., St. Louis, MO, USA) according to the manufacturer's procedure. The method was used to bind human serum HSA, IgG, fibrinogen, transferrin, IgA, IgM, haptoglobin, alpha 2-macroglobulin, alpha 1-acid glycoprotein, alpha 1-antitrypsin, Apo A-I HDL, Apo A-II HDL, complement C3 and LDL (ApoB) in order to increase lowabundance protein identification. The samples were transferred into an Amicon Ultra-0.5 mL 3 kDa centrifugal filter (Millipore, Billerica, MA, USA) following the manufacturer's procedure to collect high molecular weight proteins. The samples were then subjected to denaturation with TFE, to reduction with DTT 200 mM, to alkylation with IAM 200 mM and to complete protein digestion with 2 μg of Trypsin/Lys-C (Promega, Madison, WI, USA). The peptide digests were desalted on the Discovery® DSC-18 solid phase extraction (SPE) 96-well plate (25 mg/well) (Sigma-Aldrich Inc., St. Louis, MO, USA). The SPE plate was preconditioned with 1 mL of acetonitrile and 2 mL of water. After loading the sample, the SPE was washed with 1 mL of water. The adsorbed proteins were eluted with 800 μL of acetonitrile:water (80:20) [17] . After the desalting process, the sample was vacuum-evaporated and reconstituted with 20 μL of 0.05% formic acid in water. 2 μL of stable-isotope-labeled peptide standard (DPEVRPTSAVAA, Val-13C515N1 at V10, Cellmano Biotech Limited, Anhui, China) was spiked into the samples before the LC-MS/MS analysis and used for instrument quality control.
The preparation for plasma derivatization of fatty acids consists in collecting 30 μL of serum in PTFE screw-capped Pyrex tubes. Derivatization was performed with 2 mL of methanol acetyl chloride (10%) and 500 μL of n-hexane vigorously shaken in a water bath at 95°C for 1 h. Cooling to RT was followed by the addition of 5 mL of 6% potassium carbonate solution.
100 μL of the n-hexane top layer was transferred into a 500 μL auto-sampler vial and crimped [18] . [19, 20] .
LC-MS/MS analyses
Protein database search
The DDA files were searched using Protein Pilot software v. 4.2 (SCIEX, Concord, Canada) and Mascot v. 2.4 (Matrix Science Inc., Boston, USA). Trypsin as digestion enzyme was specified for both software. For Mascot we used 2 missed cleavages, set the instrument to ESI-QUAD-TOF and specified the following modifications for the assay: carbamidomethyl cysteine as fixed modification and oxidized methionine as variable modification. An assay tolerance of 50 ppm was specified for peptide mass tolerance, and 0.1 Da for MS/MS tolerance. The peptide charges to be detected were set to 2 +, 3 + and 4 +, and the assay was set on monoisotopic mass [21] . The UniProt Swiss-Prot reviewed database containing human proteins (version 2015.07.07, containing 42,131 sequence entries) was used and a target-decoy database search was performed. False Discovery Rate was fixed at 1%.
Protein quantification
Quantification was performed by integrating the extracted ion chromatogram of all the unique ions for a given peptide. SwathXtend was employed to build an integrated assay library with the DDA acquisitions, using a protein FDR threshold of 1% [22] .
Quantification was carried out with PeakView 2.0 and MarkerView 1.2. (ABSCIEX, Concord, Canada). Six peptides per protein and six transitions per peptide were extracted from the SWATH files. Shared peptides were excluded as well as peptides with modifications.
Peptides with FDR lower than 1.0% were exported in MarkerView for the t-test. 
GC-MS analysis
Western Blot analysis
Equal amounts of proteins extracted from serum samples were resolved on a 4-20% SDSpolyacrylamide gel and electroblotted onto PVDF membranes (Roche Diagnostic).
Membranes were then blocked in 5% non-fat dried milk in Tris-buffered saline (TBS-T, 50 mM Tris pH 7.5, 0.9% NaCl, 0.1% Tween 20) for 1 h at room temperature. Zinc-alpha-2glycoprotein (ZAG) was detected by using anti-ZAG (1D4) (1:500, Santa Cruz Biotechnology, #sc-13585) primary antibody, diluted in 1% non-fat dried milk in TBS-T for 3 h at room temperature. Blots were then incubated for 1 h at room temperature with antimouse IgGκ-Horseradish peroxidase (HRP)-conjugated secondary antibody (1:2000, Santa Cruz Biotechnology, #sc-516102). The immunocomplexes were visualized by chemiluminescence using the Chemidoc MP imaging system (Bio-Rad Laboratories). Signal intensity of the bands was measured by using Image Lab software (Bio-Rad Laboratories), and mean protein quantification was performed by two independent experiments, designed to contain three serum samples from Crohn's Disease (CD), Ulcerative Colitis (UC) and randomly selected healthy patients per blot.
ELISA assay
Kallistatin protein was analyzed with the DuoSet ELISA Human Serpin A4/Kallistatin kit (cod. DY1669, R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions.
Bioinformatics and Statistics Software
The identified proteins were classified with Funrich using a Gene ontology database [23] .
The regulated proteins were analyzed by using STRING software (http://string-db.org), which is a database of known and predicted protein-protein interactions. 
Results
The plasma proteomic and lipidomic profiles of 28 patients with IBD were studied using a shotgun proteomic approach and GC-MS, respectively. The plasma analysis of 15 patients with Crohn's disease (CD) and 13 patients with ulcerative colitis (UC) were compared to 17 healthy subjects. Fold change analysis of proteins and lipids was used to identify potential biomarkers for IBD, CD and UC, to study the pathways involved in the pathology and to better understand the biological mechanisms of the diseases. Moreover, proteomics and lipidomics data were integrated by using chemometric and bioinformatic tools to identify new combined biomarkers. Figure 1 reports the experimental workflow of this research.
Plasma protein analysis
The presence of high-abundance plasma proteins, such as albumin, may mask the under (Figure 2a ). STRING analysis of the regulated proteins showed that the disease affects proteins that are related to the acute phase response and to complement activity (up-regulation), and to the regulation of protease function, to blood coagulation and to oxygen transport (down-regulation). Gene ontology classification based on biological processes confirmed the STRING results and highlighted the down-regulation of proteins linked to lipoprotein metabolic processes (Figures 2b and   2c ). In addition, the pathway analysis performed with the Cytoscape software and the ClueGO plug-in showed an increased secretion of acute phase response protein, complement activation pathway, and a negative regulation of coagulation and oxidative processes in IBD patients ( Supplementary Figure 2) .
The plasma protein expression was also evaluated to highlight the differences between CD and UC, and to identify potential biomarkers for the two sub-classes of IBD. Figure 3 shows the heat map of log fold changes of regulated proteins in IBD, CD and UC patients, compared to healthy subjects. 42 proteins were modulated in CD patients, 17 were upregulated and 25 were down-regulated, while UC patients were characterized by 24 upregulated and 19 down-regulated proteins. Some proteins were modulated only for CD (i.e., KAIN, PRCC and GELS) or UC (i.e., LPPRC, SURF4 and CHADL), suggesting that they may be used as potential biomarkers for the sub-classification of IBD.
Validation of the proteomic results
In order to corroborate the results obtained with shotgun mass spectrometry, we selected zinc-alpha-2-glycoprotein (ZAG) and kallistatin (KAIN) for Western Blot and ELISA validation, respectively.
The expression levels of ZAG protein in CD and UC serum samples was compared to healthy subjects. As reported in Figure 4a , the relative abundance of sera levels of ZAG2 protein were significantly lower in CD and UC, in comparison to controls. Then we performed Western Blot validation by using a polyclonal antibody specific for ZAG2. As shown in figure   4b , the optical density measurements of the bands revealed an approximately 2-fold statistically significant decrease in the amount of ZAG protein in CD and UC samples, compared to healthy individuals.
The expression level of KAIN protein in CD, UC and healthy subjects was measured using the ELISA method. Briefly, MS-results revealed that the median values of the sera levels of KAIN protein were significantly lower in CD than in UC and in healthy controls (Figure 4c ).
As reported in figure 4d , the ELISA analysis performed in the same sera revealed that KAIN protein is down-regulated in CD patients, while it is not modulated in UC patients, confirming our MS-based results (Figure 4d ).
Plasma fatty acid analysis
As previously reported, the role of lipids in mucosal immunity and in chronic inflammation makes their study pivotal to understand IBD pathogenesis. A gas chromatographic analysis of plasma samples was also performed to investigate changes in the fatty acid profile between UC and CD patients. After the derivatization process and the instrumental analysis, the eluated compounds were identified by matching their raw mass spectra and retention index with previously existing databases. The fatty acids were then analyzed using bioinformatic tools to reveal modulated molecules and to underscore their main biological processes.
GC-MS analysis allowed to identify 37 non-redundant and common fatty acids for UC, CD and healthy patients. The fold change calculation was carried out by the MetaboAnalyst software: eleven fatty acids were modulated in CD patients, while only two were regulated in UC. Table 1 reports the fold changes of differentially regulated fatty acids in UC, CD and IBD (UC+CD) patients, compared to healthy subjects (fold change ≥1.5 and p-value ≤0.05).
Data integration and multivariate analysis
Integrating multi-omics data offers an unprecedented and original opportunity to assess molecular interactions and to provide new combined biomarkers for the diagnosis and prognosis of diseases. In this study we used combined ROC curves and multivariate data analysis of multi-omics data to integrate and evaluate the performance of biomarkers and models of the two IBD subclasses.
ROC curves and combined ROC for marker identification
To determine if a multi-model could improve performance over single biomarkers, we employed CombiROC software that uses combinatorial analysis to select the best combinations and ROC curves for automatic comparisons. Data were not subjected to any transformation step. All the possible combinations of modulated biomarkers (both proteins and lipids) were obtained. Table 2 reports the area under the curve (AUC), the sensitivity (SE), the specificity (SP) and the optimal cut off value for the best markers for CD and UC.
CombiROC generated ROC curves for single markers but also for a marker combo with even higher sensitivity and specificity. For UC patients, the combo LAMP2_HUMAN, PTGDS_HUMAN, SURF4_HUMAN, tridecanoic acid was found in those with the highest AUC, while for CD patients the best combo was CBG_HUMAN, KPCA_HUMAN, LITD1_HUMAN,13-Docosenoic acid,-4,7,10,13,16,19-Docosahexaenoic acid.
CombiROC analysis revealed the best combination of markers, made up of markers that would not achieve sufficient AUC, SE and SP when individually considered.
Multivariate data analysis
Proteomic and lipidomic studies, combined with multivariate data analysis methods, allowed to perform a highly efficient multifactorial biomarker analysis. Several hundreds of molecules (proteins and lipids) were measured in every single sample, obtaining an individual biochemical fingerprint. These complex profiles were converted into a data matrix, which was then analyzed using multivariate methods.
The dataset was arranged in a matrix of 40 samples (17 controls, 15 patients affected by CD and 13 patients affected by UC) and 399 variables (362 corresponding to the signal of the quantified proteins, and 37 corresponding to the signal of the quantified fatty acids).
Regarding proteins, data were first row-scaled to eliminate variations caused by minor differences in the total protein content of the initial sample, while fatty acid signals were normalized for the internal standard to eliminate random variations. Then, the complete Significance of the information about fatty acids. First of all, PLS-DA models were built based on the variables selected by the monovariate approach, both including and excluding fatty acids, to evaluate if fatty acids contain significant information about the pathology, and if they potentially include interesting markers. This evaluation was limited to the comparison of UC and CD samples vs. controls, since these two cases were the only ones for which significant markers could be identified with the monovariate approach. Table 3 Multivariate models were, therefore, calculated by always including both proteins and fatty acids.
Biomarkers for CD. CD samples were compared to both control samples and UC plus control samples. Specific markers for CD are identified in both cases; however, in the first case they allow to differentiate CD patients from healthy subjects, while in the second case the identified markers allow to differentiate CD patients not only from healthy subjects but also from patients presenting another IBD pathology (UC).
In both cases, PLS-DA was carried out between the X-block variables and a Y variable Table 4 reports the classification performance of the PLS-DA models with backward elimination variable selection (BE-PLS-DA), and of the PLS-DA models calculated including the proteins. Finally, the fatty acids were statistically significant according to the monovariate approach, and the number of LVs indicates very small cross-validation errors. In this case too, the % of variables identified as relevant by the monovariate approach included in the PLS-DA models is about 70%, thus presenting a good overlap between the two approaches.
Comparing UC and control samples, both the multivariate and the monovariate models provide 100% of correct classifications in terms of fit, with the multivariate approach providing better performance in cross-validation tests and a more exhaustive identification of candidate biomarkers, with a larger number of proteins and fatty acids identified as significant. The multivariate model's classification performance is much better both regarding fit and cross-validation, and also for the comparison between UC and other samples, while guaranteeing a more exhaustive identification of candidate biomarkers, including not only proteins but also 6 fatty acids. Other classification parameters (specificity, precision and sensitivity) are reported in Supplementary Information 2.
Discussion
Accurate classification of UC and CD patients is essential in the management of IBD due to their different response to medication, surgical indications and prognosis. Currently, the diagnosis is still not precise, and several clinical tests are required, including radiology, endoscopy and histopathology investigations [26] . Though many non-invasive biomarkers of IBD disease activity have been described, none of them has been fully validated for early diagnosis and sub-classification between CD and UC [27] .
Our proteomic results confirmed the presence in IBD sera of proteins involved in coagulation and fibrinolysis, such as complement system components, C-reactive protein (CRP), serum amyloid A (SAA) and fibronectin (FINC). This is typical of an acute-phase reaction. CRP, which is one of the most important acute-phase proteins, has been shown to correlate with disease activity and prognosis of IBD, but its specificity is unsatisfactory, and it may indicate a general inflammation [10] . Serum amyloid A, which is involved in binding and removing cholesterol from inflammatory lesions, increases in inflammatory conditions, such as CD and UC [28] . Fibronectin too can be included in this class of molecules as it is essential for wound healing and plays a central role in cell adhesion, growth, migration, and differentiation. Alterations in this protein can also be observed in other conditions, such as cancer and fibrosis [29] . Our study observed that CRP and SAA are highly expressed in IBD patients, while fibronectin is up-regulated only in CD patients.
Extensive evidence underscores the connection between inflammation, coagulation, and fibrinolysis [30] . Coagulation factor XIII A chain (F13A) and histidine-rich glycoprotein (HRG) are strongly involved in these mechanisms, and their concentrations show a tendency to decrease in our cohort. Factor XIII is the final enzyme in the coagulation cascade and is essential for hemostasis and fibrinolysis. During an inflammatory flare in CD, consumption of this factor increases in digestive mucosa, with a subsequent decrease in its serum levels [31] .
Histidine-rich glycoprotein (HRG), which regulates several physiological processes, such as tissue remodeling, angiogenesis and tumor metastasis [32] , decreases only in our UC patients: usually its levels decline significantly during acute inflammation and surgery.
Circulating HRG levels have been found to be significantly lower in patients with systemic lupus erythematosus, suggesting the active involvement of HRG during acute as well as chronic inflammation [33, 34] .
The expression of protease inhibitors in IBD is quite variable, reporting increased, decreased or stable levels of expression for serpins [35] . Kallistatin (KAIN), a human serine proteinase inhibitor, is a newly identified tissue kallikrein inhibitor. It strongly binds tissue kallikrein but weakly binds other serine proteinases, such as chymotrypsin and elastase. Down-regulation of plasma kallistatin has already been described in IBD tissues, and our data confirm this trend [36] . In fact, our CD patients showed down-regulation of KAIN, compared to healthy subjects. This was also confirmed by ELISA.
Anemia, a common systemic complication and/or extra-intestinal manifestation in IBD, is
usually defined as a decrease in the total amount of red blood cells (RBCs) or hemoglobin in blood. Anemia has already been reported in both CD and UC patients with percentages of 21% and 27%, respectively [37, 38] . Consistently, hemoglobin levels in our IBD patients are low in comparison to controls, suggesting the presence of anemia.
Plasma lipid and lipoprotein alterations in inflammatory bowel disease have already been described: there is an increase in triglycerides (TGs) due to an accumulation of very low density lipoprotein (VLDL), and a decrease in high-density lipoprotein (HDL) and apolipoprotein A-I levels, along with apolipoprotein C-I (APOC1) [39] .
Fatty acids have been historically considered simple membrane components that serve as structural elements and energy storing entities, but today they are increasingly recognized as potent signaling molecules involved in many metabolic processes. Fatty acids, particularly n-3 and n-6 polyunsaturated fatty acids (PUFAs), mediate a number of key biological processes, including eicosanoid production, inflammation, cell membrane physiological processes, and gene regulation and expression [40] . Long-chain dietary n-3
PUFAs have been shown to inhibit the expression of genes that activate inflammatory processes [41] . n-6 PUFAs are metabolized into lipid inflammatory mediators, such as prostaglandin E2 and leukotriene B4. Arachidonic acid (AA) is mobilized by phospholipase A2 family members to synthesize lipid mediators at sites of cellular damage or inflammation.
This study observed that three fatty acids are down-regulated in IBD patients, namely eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and linoleic acid (LA), which are well-known anti-inflammatory mediators in biological processes. The signaling functions of several classes of lipids discovered in the past decade resolve rather than promote inflammation [42] . E-series resolvins originate from EPA, while DHA generates the family of D-series resolvins (RvD), protectin D1, and maesins [43] . Resolvins are biosynthesized endogenously during the resolution phase of inflammation. Animal studies have revealed that RvE1, RvE2, and RvE3 inhibit leukocyte/neutrophil migration associated with a reduction in the release of pro-inflammatory cytokines and an increase in the phagocytic activity of macrophages that, in turn, cause tissue "cleaning". These results are consistent with our data: EPA was slightly lower in CD patients, compared to the controls. A reduction in the weight percentage of EPA may contribute to the exacerbation of inflammation in CD patients. Moreover, eicosapentaenoic acid is a precursor to docosahexaenoic acid (DHA): lower levels of EPA have a negative effect on DHA levels. We also found calcium metabolism dysregulation related to nervonic acid, which is an omega-9 monounsaturated fatty acid. This compound is a regulator of the Ca2+ ion channel in the cell membrane.
Patients with gut disorders are unable to retain calcium properly, and they need dietary supplements to increase its levels. Down-regulation of omega-9 MUFA is thus consistent with the onset of the disease [44] .
Down-regulated fatty acids include paulinic acid (PA), which has low levels in CD patients.
PA belongs to the omega-7 monounsaturated fatty acid family. Recent studies have reported a correlation between MUFA and anti-inflammatory effects. This novel fatty acid called omega-7 can help break the cycle of high blood sugar, elevated lipid levels, inflammation, and excess fat gain, as well as enhance insulin sensitivity. Moreover, dietary intake of omega-7 caused a reduction in C-reactive protein levels, which are closely related to this kind of pathologies [45] . Negative regulation of saturated fatty acids can be related to an inability to retain certain substances in the inflamed intestine: tridecylic, caprylic, behenic, lignoceric, arachidic and tricosylic acid showed negative fold change values.
Concluding, the use of mass spectrometry and bioinformatic techniques allows rapid and robust analysis of hundreds of biological molecules in serum. Moreover, they enable investigators to extend the analysis to proteins and metabolites that were previously not suspected of being involved in IBD pathogenesis.
It is widely deemed that serum levels of the majority of biomarkers for disease diagnosis and prognosis are low. Depletion of the major serum proteins before the final analysis allowed us to identify several potential biomarkers and a proteomic signature of CD and UC.
Moreover, since lipids play a pivotal role in IBD pathogenesis, we also investigated the lipidomic profiles of UC and CD, identifying new potential markers and lipid functions associated with IBD. We used chemometric and bioinformatic tools to identify several pathways and biological functions involved in IBD, but we also integrated the multi-omics information to discriminate between the two subclasses of CD and UC. Comparing the mono-and the multi-variate approaches, both models showed excellent classification abilities both in terms of fit and cross-validation, with the multivariate approach providing slightly better results and guaranteeing more exhaustive marker identification.
The results of this study identified potential candidate biomarkers that should be further validated in a bigger cohort. They deserve further evaluation and new hypotheses for a mechanistic investigation of IBD.
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